SuspendedNo phase
A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
Key facts
- Who runs it
- AbbVie
- Where
- Israel13 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- People taking part
- 272 people, planned
- Started
- 10 Feb 2019
- Expected to end
- 28 Feb 2027
- Type of study
- Observational
- Record updated
- 23 October 2023
- Why it stopped
- Strategic considerations
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants with diagnosed Chronic Lymphocytic Leukemia (CLL) and eligible for venetoclax as per label
- Participants for whom the physician has decided to initiate CLL treatment with venetoclax
- Participants who have been informed verbally and in writing about this study, and who do not object to their data being processed or subjected to data quality control
Who cannot take part
- Participants currently participating (or previously participated) in an interventional clinical trial within 30 days prior to venetoclax treatment initiation
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will evaluate effectiveness and safety in routine clinical practice in participants starting venetoclax treatment for Chronic Lymphocytic Leukemia (CLL).
The group in the trial
- Patients with Chronic Lymphocytic Leukemia (CLL)
Patients with diagnosed CLL and eligible to venetoclax as per label.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Post Marketing Observational Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
- Record updated
- 23 October 2023